IFCC certifies EKF Diagnostics point-of-care analyser
Global diagnostics company EKF Diagnostics has announced that its Quo-Lab HbA1c point-of-care analyser has successfully achieved International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) certification. The analyser offers laboratory-accurate results from just 4 µL of blood with a user-friendly interface.
Glycated haemoglobin (HbA1c) testing is globally recognised as the gold standard in monitoring of diabetic patients, enabling more complete control of their disease management. The IFCC maintains the JCTLM (Joint Committee for Traceability in Laboratory Medicine) endorsed reference measurement procedure for HbA1c, accepted worldwide as the analytical control for traceability of HbA1c measurement.
To participate in the program, manufacturers are required to register and report the results of 24 samples (two per month) from across the measurement range. The samples are supplied by an IFCC reference laboratory.
“The awarding of this certification allows us to report results traceable to the IFCC reference method for quantitative determination of HbA1c,” said Gavin Jones, diabetes product manager, EKF Diagnostics. “Together with the existing NGSP certification we achieved from 2012, the IFCC award demonstrates conclusively that Quo-Lab meets all of the demanding standards set by independent certifying bodies.”
CSL fellowships fund immunity research, AI-designed proteins
Australian scientists Dr Carolien van de Sandt and Dr Rhys Grinter have each been awarded CSL...
Leukaemia Foundation funds ongoing blood cancer research at UWA
The $3m in funding is understood to represent the single largest non-government investment in...
Jian Zhou Medal recognises anaesthesia, blood pressure research
The Australian Academy of Health and Medical Sciences has announced Professor Britta Regli-von...
